{"id":258073,"date":"2021-05-24T22:00:07","date_gmt":"2021-05-24T19:00:07","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/nanoparticle-based-vaccine-effective-in-preclinical-trials\/"},"modified":"2021-05-24T22:00:07","modified_gmt":"2021-05-24T19:00:07","slug":"nanoparticle-based-vaccine-effective-in-preclinical-trials","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/nanoparticle-based-vaccine-effective-in-preclinical-trials\/","title":{"rendered":"#Nanoparticle-based vaccine effective in preclinical trials"},"content":{"rendered":"<p>&#8220;<strong>#Nanoparticle-based vaccine effective in preclinical trials<\/strong>&#8221;<\/p>\n<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2021\/flu-fighter-nanopartic.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/hires\/2021\/flu-fighter-nanopartic.jpg\" data-sub-html=\"The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Credit: University at Buffalo.\">\n<figure class=\"article-img\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/scx1.b-cdn.net\/csz\/news\/800a\/2021\/flu-fighter-nanopartic.jpg\" alt=\"Flu fighter: Nanoparticle-based vaccine effective in preclinical trials\" title=\"The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Credit: University at Buffalo.\" width=\"703\" height=\"530\"\/><figcaption class=\"text-darken text-low-up text-truncate-js text-truncate mt-3\">\n                The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Credit: University at Buffalo.<br \/>\n            <\/figcaption><\/figure>\n<\/div>\n<\/div>\n<p>An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body has proven effective in preclinical studies.\n                                                <\/p>\n<p>                                                                                Described in a study published May 24 by the <i>Proceedings of the National Academy of <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/sciencee\/\" data-internallinksmanager029f6b8e52c=\"5\" title=\"Science\" target=\"_blank\" rel=\"noopener\">Science<\/a>s<\/i>, the vaccine has the potential to:<\/p>\n<ul>\n<li>Improve the effectiveness of seasonal flu vaccines, which typically work 40-60% of the time, according to the U.S. Centers for Disease Control and Prevention.<\/li>\n<li>Take less time to produce large quantities because, unlike most seasonal flu vaccines, it is not created in embryonated chicken eggs. <\/li>\n<li>Use smaller doses, thereby increasing vaccine supplies, which can be critical given the unpredictable nature of influenza.<\/li>\n<\/ul>\n<p>&#8220;The results are very encouraging&#8221;, says the study&#8217;s senior author, Jonathan Lovell, Ph.D., associate professor of biomedical engineering at the University at Buffalo.<\/p>\n<p>&#8220;Typically, flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease. The vaccine we&#8217;re developing is a recombinant protein nanoparticle vaccine that stimulates a strong immune response,&#8221; Lovell says.<\/p>\n<p>Key to the vaccine&#8217;s success is a liposome Lovell and colleagues created called cobalt-porphyrin-phospholipid, or CoPoP.<\/p>\n<p>These tiny spherical sacs, which are small enough to be considered nanoparticles, form the backbone of what is known pharmaceutical parlance as a vaccine platform, which is any underlying <a href=\"https:\/\/buradabiliyorum.com\/en\/category\/technology\/\" data-internallinksmanager029f6b8e52c=\"4\" title=\"Technology\" target=\"_blank\" rel=\"noopener\">technology<\/a> used to develop multiple vaccines.<\/p>\n<p>(While not part of this study, the platform is being utilized in clinical trials in South Korea as a COVID-19 vaccine candidate. This is a partnership between UB spinoff company POP Biotechnologies, co-founded by Lovell, and South Korean biotech company EuBiologics. POP Biotechnologies is also working with Scripps Research to study the platform in a possible HIV vaccine.)<\/p>\n<p>Alone, these liposomes do not fight disease. But they possess a special talent. They spontaneously convert virus proteins that prompt immune responses into a more potent nanoparticle format.<\/p>\n<p>&#8220;This conversion is advantageous because the dissolved proteins attach to the surface of the liposomes, where the proteins enhance the immune system&#8217;s response to disease,&#8221; says senior author Matthew Miller, Ph.D., associate professor of biochemistry and biomedical sciences at McMaster University<\/p>\n<p>In the study, the researchers introduced a group of proteins known as hemagglutinin to the CoPop liposomes. One particular hemagglutinin, known as trimeric H3 HA, triggered a strong immune response in mice.<\/p>\n<p>&#8220;The nanoparticles carry the trimeric H3 HA to the body&#8217;s immune cells, and they provoke those immune cells to respond more vigorously to the flu,&#8221; says lead author Zachary Sia, a Ph.D. candidate in Lovell&#8217;s lab.<\/p>\n<p>In experiments involving flu virus strain H3N2, blood serum from vaccinated mice was injected into non-vaccinated mice. The injection provided protection against H3N2. In experiments with ferrets involving a more modern H3N2 strain, the vaccine reduced the amount of virus in the animals&#8217; upper respiratory system.<\/p>\n<p>Even with doses as low as 2 nanograms, the vaccine provided a similar level of protection that vaccines with doses typically measured in micrograms, or roughly 1,000 times more.<\/p>\n<p>&#8220;The dose-sparing effect is important because it means we could create many more doses using less materials&#8221; says senior co-author Bruce Davidson, Ph.D., research associate professor of anesthesiology in the Jacobs School of Medicine and Biomedical Sciences at UB. &#8220;Simply put, CoPoP likely will provide greater immune protection with less hemagglutinin than current vaccines.&#8221;<\/p>\n<p>The vaccine platform is also versatile.<\/p>\n<p>Researchers were able to simultaneously bind 10 recombinant proteins representing distinct influenza virus strains to generate a highly multivalent nanoparticle. A 5 nanogram dose in mice offered protection against the H5N1 flu strain, more commonly known as bird flu, a virus that epidemiologists say has the potential to trigger a pandemic.\n                                                                                                                        <\/p>\n<hr\/>\n<div class=\"article-main__explore my-4 d-print-none\">\n<p>                                                                                        Intranasal influenza vaccine enhances immune response and offers broad protection, researchers find\n                                                                                    <\/p><\/div>\n<hr class=\"mb-4\"\/>\n<div class=\"article-main__more p-4\">\n                                                                                                <strong>More information:<\/strong><br \/>\n                                                Zachary R. Sia el al., &#8220;A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge,&#8221; <i>PNAS<\/i> (2021). <a rel=\"nofollow noopener\" target=\"_blank\" href=\"https:\/\/www.pnas.org\/cgi\/doi\/10.1073\/pnas.2025759118\">www.pnas.org\/cgi\/doi\/10.1073\/pnas.2025759118<\/a><\/p><\/div>\n<div class=\"d-inline-block text-medium my-4\">\n                                                Provided by<br \/>\n                                                                                                    University at Buffalo<br \/>\n                                                                                                        <a rel=\"nofollow noopener\" target=\"_blank\" class=\"icon_open\" href=\"http:\/\/www.buffalo.edu\/\"><br \/>\n                                                        <svg><use href=\"https:\/\/medx.b-cdn.net\/tmpl\/v6\/img\/svg\/sprite.svg#icon_open\" x=\"0\" y=\"0\"\/><\/svg><\/a><\/p><\/div>\n<p>                                        <!-- print only --><\/p>\n<div class=\"d-none d-print-block\">\n<p>\n                                                 <strong>Citation<\/strong>:<br \/>\n                                                 Flu fighter: Nanoparticle-based vaccine effective in preclinical trials (2021, May 24)<br \/>\n                                                 retrieved 24 May 2021<br \/>\n                                                 from https:\/\/medicalxpress.com\/<a href=\"https:\/\/buradabiliyorum.com\/en\/category\/news\/\" data-internallinksmanager029f6b8e52c=\"2\" title=\"News\" target=\"_blank\" rel=\"noopener\">news<\/a>\/2021-05-flu-fighter-nanoparticle-based-vaccine-effective.html<\/p>\n<p>                                            This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no<br \/>\n                                            part may be reproduced without the written permission. The content is provided for information purposes only.<\/p><\/div>\n<\/p><\/div>\n<p><script id=\"facebook-jssdk\" async=\"\" src=\"https:\/\/connect.facebook.net\/en_US\/sdk.js\"><\/script><\/p>\n<blockquote><p><strong><span style=\"color: #ff6600;\">If you liked the article, do not forget to share it with your friends. Follow us on\u00a0<span style=\"color: #ff0000;\"><a style=\"color: #ff0000;\" href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMLG0nwswvr63Aw\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\">For forums sites go to <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/forum.buradabiliyorum.com\/\" target=\"_blank\" rel=\"noopener\">Forum.BuradaBiliyorum.Com<\/a><\/span><\/strong>\n<\/p><\/blockquote>\n<blockquote>\n<p style=\"text-align: center;\"><strong>If you want to read more Like this articles, you can visit our <span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/en.buradabiliyorum.com\/science\/\" target=\"_blank\" rel=\"noopener\">Science category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n<p><span style=\"color: black;\"><a style=\"color: #ff9900;\" href=\"https:\/\/medicalxpress.com\/news\/2021-05-flu-fighter-nanoparticle-based-vaccine-effective.html\" target=\"_blank\" rel=\"noopener\">Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;#Nanoparticle-based vaccine effective in preclinical trials&#8221; The circle-shaped objects in the image above are cobalt-porphyrin-phospholipid (CoPoP) nanoparticles decorated with flu proteins. Credit: University at Buffalo. An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body has proven effective in preclinical studies. Described in a study published May&#8230;<\/p>\n","protected":false},"author":1,"featured_media":258074,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/scx2.b-cdn.net\/gfx\/news\/hires\/2021\/flu-fighter-nanopartic.jpg","fifu_image_alt":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-258073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciencee"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/258073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=258073"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/258073\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/258074"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=258073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=258073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=258073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}